Top Markets
#1 Useless Coin Useless Coin +38.89%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.87%
#3 0G 0G +35.68%
#4 StonkBroker StonkBroker +33.02%
#5 SAFEcoin SAFEcoin +30.29%
#6 Zora Zora +20.93%
#7 Arbitrum Arbitrum +20.92%
#8 Full Moon Full Moon +18.06%
#9 Dogs Dogs +17.66%
#10 Notcoin Notcoin +17.14%
Coin of the day
Useless Coin Useless Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Rank in Stocks #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Share Price
$4.36
Market Cap
$457.32M
Change (1 day)
0.69%
Change (1 year)
289.29%
Country
US
Trade Relmada Therapeutics, Inc. (RLMD)

Category

Healthcare
Revenue for Relmada Therapeutics, Inc. (RLMD)
Revenue in Aug 2026 TTM: 0
According to Relmada Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Relmada Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH